Key result
QT-prolonging drugs like methadone trigger severe QTc prolongation in up to ~16% of patients.
Why the study?
What is the incidence of significant QTc prolongation and torsades de pointes in adult patients exposed to QT-prolonging medications?
Systematic Review (n=14,756)
Yes
What is the incidence of significant QTc prolongation and torsades de pointes in adult patients exposed to QT-prolonging medications?
Significant QTc prolongation (>500 ms) is relatively common among adults taking QT-prolonging medications, though progression to torsades de pointes remains rare, highlighting the need for standardized ECG monitoring.
Supports routine DDI screening in psychiatric prescribing; leaves open absolute TdP risk and need for outcome trials.
Objectives: To systematically evaluate the incidence and prevalence of drug-induced QT interval prolongation and torsades de pointes (TdP) among adults exposed to QT-prolonging medications. Design: Systematic review of observational and interventional studies identified through MEDLINE (via PubMed). Setting: Primary and secondary care settings, including inpatient and outpatient populations, across multiple geographical regions. Participants: Adult patients (18 years and older) receiving QT-prolonging drugs and undergoing electrocardiographic monitoring. Studies reporting QTc prolongation using predefined thresholds were eligible. A total of 14,756 participants were included across 42 studies. Intervention: Exposure to QT-prolonging medications. Primary and Secondary Outcomes: The primary outcome was the incidence or prevalence of significant QTc prolongation, defined as QTc >500 ms or an increase in QTc (ΔQTc) ≥60 ms. The secondary outcome was the occurrence of TdP. Results: Of 501 records, 42 studies met the inclusion criteria: 5 were interventional and 37 observational, involving a total of 14,756 patients. Methadone was the most frequently studied drug (17 studies), with reported QTc >500 ms incidence ranging from 0% to 16.2%, and TdP prevalence up to 3.6% and incidence of up to 3.2%. Other frequently studied drugs included hydroxychloroquine (5 studies), azithromycin (4 studies), and antipsychotics such as haloperidol and quetiapine. Incidence of QTc >500 ms varied considerably across settings and drug classes, influenced by heterogeneous QTc correction formulas. Conclusions: Drug-induced QTc prolongation is not uncommon across a range of widely used medications, especially in psychiatric care, yet its monitoring and risk remain inconsistently assessed, particularly in outpatient settings. While TdP was rarely reported, QTc >500 ms occurred with notable frequency. Significant heterogeneity in QTc definitions, study populations, and ECG methodologies limits cross-study comparability, underscoring the need for greater standardization.
No takes yet. Share an insight, caveat, or question.
Hagiu et al. (2026) conducted a systematic review in Exposure to QT-prolonging medications (n=14,756). QT-prolonging medications was evaluated on Incidence or prevalence of significant QTc prolongation (QTc >500 ms or ΔQTc ≥60 ms). Exposure to QT-prolonging medications, particularly methadone, resulted in an incidence of QTc >500 ms ranging from 0% to 16.2% and torsades de pointes incidence up to 3.2%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: